For You
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      For You News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases

      dopamine (Rx)

      Brand and Other Names:Intropin
      • Print

      Dosing & Uses

      AdultPediatric

      Dosage Forms & Strengths

      infusion solution, in D5W

      • 80mg/100mL
      • 160mg/100mL
      • 320mg/100mL

      injectable solution

      • 40mg/mL
      • 80mg/mL
      • 160mg/mL

      Hemodynamic Conditions

      Treatment of hypotension, low cardiac output, poor perfusion of vital organs; used to increase mean arterial pressure in septic shock patients who remain hypotensive after adequate volume expansion

      1-5 mcg/kg/min IV (low dose): May increase urine output and renal blood flow  

      5-15 mcg/kg/min IV (medium dose): May increase renal blood flow, cardiac output, heart rate, and cardiac contractitlity

      20-50 mcg/kg/min IV (high dose): May increase blood pressure and stimulate vasoconstriction; may not have a beneficial effect in blood pressure; may increase risk of tachyarrhythmias

      May increase infusion by 1-4 mcg/kg/min at 10-30 min intervals until optimum response obtained

      Titrate to desired response

      Dosing Considerations

      Strong beta1-adrenergic, alpha-adrenergic, and dopaminergic effects are based on dosing rate

      Beta1 effects: 2-10 mcg/kg/min

      Alpha effects: >10 mcg/kg/min

      Dopaminergic effects: 0.5-2 mcg/kg/min

      Dosage Forms & Strengths

      infusion solution, in D5W

      • 80mg/100mL
      • 160mg/100mL
      • 320mg/100mL

      injectable solution

      • 40mg/mL
      • 80mg/mL
      • 160mg/mL

      Hemodynamic Conditions

      Treatment of hypotension

      1-5 mcg/kg/min IV, increased to 5-20 mcg/kg/min; not to exceed 50 mcg/kg/min  

      Titrate to desired response

      Prevention of Intraventricular Hemorrhage (Orphan)

      Orphan designation for prevention of intraventricular hemorrhage in premature neonates

      Sponsor

      • Brepco Biopharma, Ltd; 1785 Old Mill Road; Bethlehem, Pennsylvania 18015
      Next:

      Interactions

      Interaction Checker

      and dopamine

      No Results

         activity indicator 
        No Interactions Found
        Interactions Found

        Contraindicated

          Serious - Use Alternative

            Significant - Monitor Closely

              Minor

                All Interactions Sort By:
                 activity indicator 

                Contraindicated (6)

                • isocarboxazid

                  isocarboxazid increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                • linezolid

                  linezolid increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                • lurasidone

                  dopamine increases toxicity of lurasidone by Other (see comment). Contraindicated. Comment: Interaction applies only in setting of acute lurasidone overdose. Epinephrine may enhance hypotensive effects of lurasidone in overdose setting.

                • phenelzine

                  phenelzine increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                • selegiline transdermal

                  selegiline transdermal increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                • tranylcypromine

                  tranylcypromine increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                Serious - Use Alternative (55)

                • amitriptyline

                  amitriptyline, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • amoxapine

                  amoxapine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • aripiprazole

                  aripiprazole decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • benperidol

                  benperidol decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • cabergoline

                  cabergoline, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

                • chlorpromazine

                  chlorpromazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • clomipramine

                  clomipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • clozapine

                  clozapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • desflurane

                  desflurane increases toxicity of dopamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

                • desipramine

                  desipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • dihydroergotamine

                  dihydroergotamine, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

                • dihydroergotamine intranasal

                  dihydroergotamine intranasal, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

                • doxapram

                  doxapram increases effects of dopamine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive pressor effect.

                • doxepin

                  doxepin, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • droperidol

                  droperidol decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • ergoloid mesylates

                  ergoloid mesylates, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

                • ergotamine

                  ergotamine, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

                • ether

                  ether increases toxicity of dopamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

                • ethotoin

                  ethotoin, dopamine. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of hypotension.

                • fluphenazine

                  fluphenazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • fosphenytoin

                  fosphenytoin, dopamine. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of hypotension.

                • haloperidol

                  haloperidol decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • iloperidone

                  iloperidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • imipramine

                  imipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • isoflurane

                  isoflurane increases toxicity of dopamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

                • lofepramine

                  lofepramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • loxapine

                  loxapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • loxapine inhaled

                  loxapine inhaled decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • maprotiline

                  maprotiline, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • methoxyflurane

                  methoxyflurane increases toxicity of dopamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

                • methylergonovine

                  methylergonovine, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

                • metoclopramide

                  metoclopramide decreases levels of dopamine by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated.

                  metoclopramide decreases levels of dopamine by pharmacodynamic antagonism. Contraindicated.

                • nortriptyline

                  nortriptyline, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • olanzapine

                  olanzapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • ozanimod

                  ozanimod increases toxicity of dopamine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.

                • paliperidone

                  paliperidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • perphenazine

                  perphenazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • phenytoin

                  phenytoin, dopamine. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of hypotension.

                • pimozide

                  pimozide decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • ponesimod

                  ponesimod, dopamine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients.

                • prochlorperazine

                  prochlorperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • promethazine

                  promethazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • protriptyline

                  protriptyline, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • quetiapine

                  quetiapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • risperidone

                  risperidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • sevoflurane

                  sevoflurane increases toxicity of dopamine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

                • tafenoquine

                  tafenoquine will increase the level or effect of dopamine by Other (see comment). Avoid or Use Alternate Drug. Tafenoquine inhibits organic cation transporter-2 (OCT2) and multidrug and toxin extrusion (MATE) transporters in vitro. Avoid coadministration with OCT2 or MATE substrates. If coadministration cannot be avoided, monitor for substrate-related toxicities and consider dosage reduction if needed based on product labeling of the coadministered drug.

                • thioridazine

                  thioridazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • thiothixene

                  thiothixene decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • trazodone

                  trazodone, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • trifluoperazine

                  trifluoperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                • trilaciclib

                  trilaciclib will decrease the level or effect of dopamine by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities.

                • trimipramine

                  trimipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

                • yohimbe

                  yohimbe, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                • ziprasidone

                  ziprasidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

                Monitor Closely (172)

                • albuterol

                  albuterol and dopamine both decrease sedation. Use Caution/Monitor.

                  albuterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • alfentanil

                  alfentanil increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • alprazolam

                  alprazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • amitriptyline

                  amitriptyline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • amobarbital

                  amobarbital increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • amoxapine

                  amoxapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • arformoterol

                  arformoterol and dopamine both decrease sedation. Use Caution/Monitor.

                  arformoterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • aripiprazole

                  aripiprazole increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • armodafinil

                  armodafinil and dopamine both decrease sedation. Use Caution/Monitor.

                • atomoxetine

                  atomoxetine, dopamine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as dopamine.

                • azelastine

                  azelastine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • belladonna and opium

                  belladonna and opium increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • benperidol

                  benperidol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • benzphetamine

                  benzphetamine and dopamine both decrease sedation. Use Caution/Monitor.

                  benzphetamine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • bretylium

                  bretylium increases effects of dopamine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Modify Therapy/Monitor Closely. If catecholamines are administered to treat systolic BP <75 mmHg, a dilute solution should be employed and blood pressure monitored closely. Bretylium causes an initial norepinephrine release and may enhance catecholamine pressor effects.

                • bromocriptine

                  bromocriptine and dopamine both increase dopaminergic effects. Use Caution/Monitor.

                  bromocriptine, dopamine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach.

                • brompheniramine

                  brompheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • buprenorphine buccal

                  buprenorphine buccal increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • butabarbital

                  butabarbital increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • butalbital

                  butalbital increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • butorphanol

                  butorphanol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • cabergoline

                  cabergoline and dopamine both increase dopaminergic effects. Use Caution/Monitor.

                • caffeine

                  caffeine and dopamine both decrease sedation. Use Caution/Monitor.

                • carbinoxamine

                  carbinoxamine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • chloral hydrate

                  chloral hydrate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • chlordiazepoxide

                  chlordiazepoxide increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • chlorpheniramine

                  chlorpheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • chlorpromazine

                  chlorpromazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  chlorpromazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • cinnarizine

                  cinnarizine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • clemastine

                  clemastine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • clomipramine

                  clomipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • clonazepam

                  clonazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • clorazepate

                  clorazepate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • clozapine

                  clozapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • codeine

                  codeine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • cyclizine

                  cyclizine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • cyproheptadine

                  cyproheptadine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • deflazacort

                  dopamine and deflazacort both decrease serum potassium. Use Caution/Monitor.

                • desipramine

                  desipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • dexchlorpheniramine

                  dexchlorpheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • dexfenfluramine

                  dexfenfluramine and dopamine both decrease sedation. Use Caution/Monitor.

                  dexfenfluramine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • dexmedetomidine

                  dexmedetomidine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • dexmethylphenidate

                  dexmethylphenidate and dopamine both decrease sedation. Use Caution/Monitor.

                  dexmethylphenidate and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • dextroamphetamine

                  dextroamphetamine and dopamine both decrease sedation. Use Caution/Monitor.

                  dextroamphetamine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • dextromoramide

                  dextromoramide increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • diamorphine

                  diamorphine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • diethylpropion

                  diethylpropion and dopamine both decrease sedation. Use Caution/Monitor.

                  diethylpropion and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • difenoxin hcl

                  difenoxin hcl increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • digoxin

                  dopamine increases toxicity of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Can increase risk of cardiac arrhythmias.

                • dimenhydrinate

                  dimenhydrinate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • diphenhydramine

                  diphenhydramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • diphenoxylate hcl

                  diphenoxylate hcl increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • dipipanone

                  dipipanone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • dobutamine

                  dobutamine and dopamine both decrease sedation. Use Caution/Monitor.

                  dobutamine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • dopexamine

                  dopexamine and dopamine both decrease sedation. Use Caution/Monitor.

                  dopexamine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • doxepin

                  doxepin increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • droperidol

                  droperidol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • entacapone

                  entacapone will increase the level or effect of dopamine by decreasing metabolism. Use Caution/Monitor. Entacapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

                • ephedrine

                  ephedrine and dopamine both decrease sedation. Use Caution/Monitor.

                  ephedrine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • epinephrine

                  epinephrine and dopamine both decrease sedation. Use Caution/Monitor.

                  epinephrine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • epinephrine racemic

                  epinephrine racemic and dopamine both decrease sedation. Use Caution/Monitor.

                  epinephrine racemic and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • erdafitinib

                  dopamine increases levels of erdafitinib by decreasing renal clearance. Modify Therapy/Monitor Closely. Consider alternatives that are not OCT2 substrates or consider reducing the dose of OCT2 substrates based on tolerability.

                • estazolam

                  estazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • ethanol

                  ethanol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • fenfluramine

                  dopamine and fenfluramine both decrease sedation. Use Caution/Monitor.

                  dopamine and fenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • fluphenazine

                  fluphenazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  fluphenazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • flurazepam

                  flurazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • formoterol

                  formoterol and dopamine both decrease sedation. Use Caution/Monitor.

                  formoterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • green tea

                  green tea increases effects of dopamine by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase CNS stimulatory effects due to caffeine in green tea.

                • haloperidol

                  haloperidol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • hydralazine

                  hydralazine, dopamine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Sympathomimetics can antagonize the activity of some antihypertensive agents.

                • hydromorphone

                  hydromorphone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • hydroxyzine

                  hydroxyzine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • iloperidone

                  iloperidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • imipramine

                  imipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • indacaterol, inhaled

                  dopamine increases effects of indacaterol, inhaled by Other (see comment). Use Caution/Monitor. Comment: If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of indacaterol may be potentiated.

                • isoproterenol

                  isoproterenol and dopamine both decrease sedation. Use Caution/Monitor.

                  isoproterenol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • ketotifen, ophthalmic

                  ketotifen, ophthalmic increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • levalbuterol

                  levalbuterol and dopamine both decrease sedation. Use Caution/Monitor.

                  levalbuterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • levorphanol

                  levorphanol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • lisdexamfetamine

                  lisdexamfetamine and dopamine both decrease sedation. Use Caution/Monitor.

                  dopamine and lisdexamfetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • lisuride

                  dopamine and lisuride both increase dopaminergic effects. Use Caution/Monitor.

                  lisuride, dopamine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

                • lofepramine

                  lofepramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • lofexidine

                  lofexidine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • loprazolam

                  loprazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • lorazepam

                  lorazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • lormetazepam

                  lormetazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • loxapine

                  loxapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • loxapine inhaled

                  loxapine inhaled increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • maprotiline

                  maprotiline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • marijuana

                  marijuana increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • melatonin

                  melatonin increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • meperidine

                  meperidine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • meprobamate

                  meprobamate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • metaproterenol

                  metaproterenol and dopamine both decrease sedation. Use Caution/Monitor.

                  metaproterenol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • methadone

                  methadone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • methamphetamine

                  methamphetamine and dopamine both decrease sedation. Use Caution/Monitor.

                  dopamine and methamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • methyldopa

                  dopamine and methyldopa both increase dopaminergic effects. Use Caution/Monitor.

                  methyldopa increases effects of dopamine by unknown mechanism. Use Caution/Monitor.

                • methylenedioxymethamphetamine

                  methylenedioxymethamphetamine and dopamine both decrease sedation. Use Caution/Monitor.

                  dopamine and methylenedioxymethamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • methylergonovine

                  methylergonovine, dopamine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive peripheral vasoconstriction.

                • methylphenidate

                  dopamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • midazolam

                  midazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • midodrine

                  dopamine and midodrine both decrease sedation. Use Caution/Monitor.

                  dopamine and midodrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • mirtazapine

                  mirtazapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • modafinil

                  modafinil and dopamine both decrease sedation. Use Caution/Monitor.

                • morphine

                  morphine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • motherwort

                  motherwort increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • moxonidine

                  moxonidine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • nabilone

                  nabilone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • nalbuphine

                  nalbuphine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • nateglinide

                  dopamine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.

                • norepinephrine

                  norepinephrine and dopamine both decrease sedation. Use Caution/Monitor.

                  norepinephrine and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • nortriptyline

                  nortriptyline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • olanzapine

                  olanzapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • olodaterol inhaled

                  dopamine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effects

                • opicapone

                  opicapone will increase the level or effect of dopamine by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

                • opium tincture

                  opium tincture increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxazepam

                  oxazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxycodone

                  oxycodone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxymorphone

                  oxymorphone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxytocin

                  oxytocin increases effects of dopamine by pharmacodynamic synergism. Use Caution/Monitor.

                • paliperidone

                  paliperidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • papaveretum

                  papaveretum increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pentazocine

                  pentazocine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pentobarbital

                  pentobarbital increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • perphenazine

                  perphenazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  perphenazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • phendimetrazine

                  dopamine and phendimetrazine both decrease sedation. Use Caution/Monitor.

                  dopamine and phendimetrazine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • phenobarbital

                  phenobarbital increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • phentermine

                  phentermine and dopamine both decrease sedation. Use Caution/Monitor.

                  dopamine and phentermine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • phenylephrine

                  dopamine and phenylephrine both decrease sedation. Use Caution/Monitor.

                  dopamine and phenylephrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • phenylephrine PO

                  dopamine and phenylephrine PO both decrease sedation. Use Caution/Monitor.

                  dopamine and phenylephrine PO both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • pholcodine

                  pholcodine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pimozide

                  pimozide increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pirbuterol

                  pirbuterol and dopamine both decrease sedation. Use Caution/Monitor.

                  pirbuterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • primidone

                  primidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • procarbazine

                  procarbazine increases effects of dopamine by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.

                • prochlorperazine

                  prochlorperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  prochlorperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • promazine

                  promazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • promethazine

                  promethazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  promethazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • propylhexedrine

                  dopamine and propylhexedrine both decrease sedation. Use Caution/Monitor.

                  dopamine and propylhexedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • protriptyline

                  protriptyline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pseudoephedrine

                  dopamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • quazepam

                  quazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • quetiapine

                  quetiapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • rasagiline

                  rasagiline increases effects of dopamine by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.

                • risperidone

                  risperidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • salmeterol

                  salmeterol and dopamine both decrease sedation. Use Caution/Monitor.

                  salmeterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • scullcap

                  scullcap increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • secobarbital

                  secobarbital increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • shepherd's purse

                  shepherd's purse increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol

                  dopamine and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.

                • solriamfetol

                  dopamine and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • sufentanil

                  sufentanil increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • tapentadol

                  tapentadol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • temazepam

                  temazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • terbutaline

                  terbutaline and dopamine both decrease sedation. Use Caution/Monitor.

                  terbutaline and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • thioridazine

                  thioridazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  thioridazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • thiothixene

                  thiothixene increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • tolcapone

                  tolcapone will increase the level or effect of dopamine by decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

                • topiramate

                  topiramate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

                • tramadol

                  tramadol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • trazodone

                  trazodone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • triazolam

                  triazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • triclofos

                  triclofos increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • trifluoperazine

                  trifluoperazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  trifluoperazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

                • trimipramine

                  trimipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • triprolidine

                  triprolidine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • vandetanib

                  vandetanib increases levels of dopamine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Vandetanib inhibits the uptake of substrates of organic cation transporter type 2 (OCT2).

                • xylometazoline

                  dopamine and xylometazoline both decrease sedation. Use Caution/Monitor.

                  dopamine and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • yohimbine

                  yohimbine and dopamine both decrease sedation. Use Caution/Monitor.

                  dopamine and yohimbine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

                • ziconotide

                  ziconotide increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • ziprasidone

                  ziprasidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                Minor (4)

                • desmopressin

                  desmopressin increases effects of dopamine by pharmacodynamic synergism. Minor/Significance Unknown.

                • eucalyptus

                  eucalyptus increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.

                • isavuconazonium sulfate

                  isavuconazonium sulfate will increase the level or effect of dopamine by Other (see comment). Minor/Significance Unknown. Isavuconazonium sulfate, an OCT2 inhibitor, may increase the effects or levels of OCT2 substrates.

                • sage

                  sage increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Cardiovascular: Ventricular arrhythmia, atrial fibrillation (at very high doses), ectopic beats, tachycardia, anginal pain, palpitation, cardiac conduction abnormalities, widened QRS complex, bradycardia, hypotension, hypertension, vasoconstriction

                Respiratory: Dyspnea

                Gastrointestinal: Nausea, vomiting

                Metabolic/nutritional: Azotemia

                Central nervous system: Headache, anxiety

                Endocrine: Piloerection

                Ocular: Increased intraocular pressure; dilated pupils

                Gangrene of extremities has occurred when high doses were administered for prolonged periods or in patients with occlusive vascular disease receiving low doses of dopamine hydrochloride

                Previous
                Next:

                Warnings

                Black Box Warnings

                May cause peripheral ischemia in patients with history of occlusive vascular disease

                If ischemia occurs, prevent sloughing and necrosis in ischemic areas by infiltrating areas as soon as possible with 5-10 mg of phentolamine (adrenergic blocking agent) in 10-15 mL of saline solution

                Contraindications

                Hypersensitivity to dopamine, pheochromocytoma, ventricular fibrillation, uncorrected tachyarrhythmias

                Cautions

                Use caution in angina pectoris, extravasation, hypovolemia, occlusive vascular disease, ventricular arrhythmias, recent use of monoamine oxidase inhibitors, sensitivity to sulfites

                Drug is inactivated by alkali

                May cause increases in heart rate

                Use with caution after myocardial infarction

                Monitor blood pressure closely

                Use caution in patients taking MAO inhibitors; prolong hypertension may occur with concurrent use

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy category: C

                Lactation: Unknown whether drug is excreted into breast milk; use caution

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Endogenous catecholamine, acting on both dopaminergic and adrenergic neurons

                Low dose stimulates mainly dopaminergic receptors, producing renal and mesenteric vasodilation; higher dose stimulates both beta1-adrenergic and dopaminergic receptors, producing cardiac stimulation and renal vasodilation; large dose stimulates alpha-adrenergic receptors

                Absorption

                Onset: 5 min (adults)

                Duration: <10 min

                Distribution

                Vd: 1.8-2.45 L/kg

                Metabolism

                Metabolized in liver, kidney, and plasma by monoamine oxidase and catechol-O-methyl transferase

                Metabolites: Norepinephrine (active), inactive metabolites

                Elimination

                Half-life: 2 min

                Total body clearance: 115 mL/kg/min

                Excretion: Urine (80%)

                Previous
                Next:

                Administration

                IV Incompatibilities

                Solution: Sodium bicarbonate 5%

                Additive: Acyclovir, alteplase, amphotericin B, ampicillin, gentamicin(?), metronidazole/sodium bicarbonate, penicillin G potassium

                Y-site: Acyclovir, aldesleukin(?), alteplase, amphotericin B cholesteryl sulfate, cefepime, furosemide(?; depends on formulation), heparin (in D5W), indomethacin, insulin, thiopental, TNA #222-223

                IV Compatibilities

                Solution: Most common solvents (eg, D5W, D10W, dextrose/saline, LR, NS, sodium lactate 1/6M)

                Additive (partial list): Aminophylline, calcium gluconate, ciprofloxacin, dobutamine, heparin, hydrocortisone, lidocaine, nitroglycerin, potassium chloride, verapamil

                Syringe: Caffeine, doxapram, heparin, ranitidine

                Y-site (partial list): Amiodarone, cisatracurium, diltiazem, dobutamine, epinephrine, esmolol, fentanyl, heparin (in NS), hydrocortisone sodium succinate, labetalol, lidocaine, lorazepam, morphine sulfate, nitroglycerin, ondansetron, potassium chloride, propofol, tacrolimus, verapamil, vitamins B and C, warfarin, zidovudine

                Not specified: Carbenicillin, tetracycline, iron salts, oxidizing agents, alkaline solutions

                IV Preparation

                Dilute 200-400 mg in 250-500 mL of compatible diluent (eg, D5W, NS, LR, D5/NS, D5/LR); typical concentration range is 0.8-1.6 mg/mL, though up to 3.2 mg/mL has been used

                Drug is stable for 24 hours after dilution

                Premixed solution may be administered without dilution

                Do not use if solution is darker than slightly yellow; discoloration to brown, pink, or purple indicates decomposition

                IV Administration

                Infuse via central line; umbilical arterial catheter is not recommended

                Administer in large vein (eg, antecubital)

                Use infusion pump to control flow rate

                Titrate dosage to desired hemodynamic values or optimal urine flow

                Previous
                Next:

                Images

                BRAND FORM. UNIT PRICE PILL IMAGE
                dopamine intravenous
                -
                		400 mg/5 mL (80 mg/mL) vial
                dopamine intravenous
                -
                		800 mg/5 mL (160 mg/mL) vial
                dopamine intravenous
                -
                		400 mg/10 mL (40 mg/mL) vial
                dopamine intravenous
                -
                		200 mg/5 mL (40 mg/mL) vial
                dopamine intravenous
                -
                		400 mg/10 mL (40 mg/mL) vial
                dopamine intravenous
                -
                		200 mg/5 mL (40 mg/mL) vial

                Copyright © 2010 First DataBank, Inc.

                Previous
                Next:

                Patient Handout

                Patient Education
                dopamine intravenous

                NO MONOGRAPH AVAILABLE AT THIS TIME

                USES: Consult your pharmacist.

                HOW TO USE: Consult your pharmacist.

                SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

                PRECAUTIONS: Consult your pharmacist.

                DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

                OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

                NOTES: No monograph available at this time.

                MISSED DOSE: Consult your pharmacist.

                STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

                Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

                IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Create Your List of Plans

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                View explanations for tiers and restrictions
                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                CLOSE
                Additional Offers
                CLOSE
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                CLOSE
                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
                Find Us On
                About
                About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
                Membership
                Become a Member About You Professional Information Newsletters & Alerts
                Apps
                Medscape CME & Education
                WebMD Network
                Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate
                Editions
                English Deutsch Español Français Português
                All material on this website is protected by copyright, Copyright © 1994-2022 by WebMD LLC. This website also contains material copyrighted by 3rd parties.